News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

World’s largest radiology AI marketplace CARPL raises $6m to accelerate the adoption of AI in clinical workflows

CARPL

As people live longer and as emphasis on early detection of disease increases, there is a mounting burden on the healthcare services industry globally. This is being especially felt in radiology teams who are witnessing an acute shortage of radiologists. Currently, there are over 200 companies building applications using AI to automate parts of the radiologists’ work to bridge this talent gap. Today CARPL, an enterprise imaging AI marketplace platform, is announcing a $6m funding round to enable healthcare providers to access, assess and integrate these radiology AI applications into their clinical workflows through a single user-interface, single data channel and single procurement system. The seed funding round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from strategic angel investors* from Novo Holdings, Leapfrog PE, Bain & Co, Boston Consulting Group, UnitedHealth Group among others. CARPL will use the fresh funds to expand the team in North America and continue to build its tech stack. With more than 700 US-FDA approved AI applications, healthcare providers grapple with navigating the complex landscape of niche AI solutions. The daunting task involves determining the best AI solution for them and their patients, then seamlessly integrating it in the radiologists' workflows. This complexity has resulted in the sluggish pace of AI adoption in healthcare. A recent joint statement by the world’s top radiology associations also brings to light the importance of validation, deployment and monitoring of AI while being used in clinical practice. CARPL’s technology platform addresses this need using its proprietary DEV-D framework allowing healthcare providers to first Discover (D), Explore (E) and Validate (V) AI applications from CARPL’s AI marketplace, and subsequently Deploy (D) the most appropriate application across their clinical workflows. CARPL stands out as the only platform in the market with deep AI validation and monitoring capabilities, thereby ensuring safe and seamless AI deployment while upholding patient-centricity at its core. Additionally, CARPL’s universal AI viewer serves as a single user interface for radiologists, enabling them to accept, reject or refine AI outputs, which can subsequently be used to improve the performance of the AI itself. Operational since 2021, CARPL was founded by Vidur Mahajan, a physician with an MBA from the Wharton School of Business who has spent more than 12 years in the diagnostics industry. CARPL’s leadership comprises Dr Vasanth Venugopal as Chief Medical Officer, Rohit Takhar as CTO and most recently Dhruv Sahai as COO. CARPL has also ramped up its advisory team with the appointment of Dr Vijay Rao, SVP of Enterprise Imaging at Jefferson Health and a past-President of the Radiology Society of North America. “Over the past two years, we have onboarded more than 50 AI developers having 100+ AI applications, which made us the largest AI marketplace in terms of number of AI applications offered to customers. We are proud that some of the largest healthcare enterprises in the world have vetted our technology and trust us to be their partner in their AI and automation journeys.” said Dr Vidur Mahajan, CEO of CARPL. Drawing parallels with the lab medicine industry, Vidur Mahajan added: “We are democratizing radiology in the same way that automation and robotics revolutionized lab medicine, where a single pathologist signs out thousands of tests each day. We envision a future where CARPL creates ‘super-radiologists’ - AI-enabled radiologists who are ten times more productive than traditional radiologists.” Vidur Mahajan brings deep domain expertise having previously grown revenue 10x to $20m in 10 years at his family business Mahajan Imaging, a leading radiology service provider. He conceptualized CARPL under the guidance of his father Dr Harsh Mahajan, a pioneer in radiology, while working on validation and deployment of AI at Mahajan Imaging. CARPL comprises a multidisciplinary team with clinicians, scientists, engineers and business experts, all working towards the singular goal of driving exponential health outcomes using the encapsulated value of the entire AI ecosystem with the ultimate aim of ensuring access of quality diagnostics to patients. CARPL has more than 120 papers and conference presentations to its credit, and has coined some seminal concepts in clinical AI such as algorithmic audits, clinical explainability failure and unboxing AI. CARPL’s technology platform is used by the world’s top healthcare organizations like the Singapore Government, Massachusetts General Hospital (Boston), Radiology Partners (Los Angeles), University Hospitals (Cleveland), I-MED Radiology (Australia), Albert Einstein Hospital (São Paulo), Clinton Health Access Initiative, to name a few. CARPL is also creating impact in the public health space by working with the Government of India to enable large scale Tuberculosis Screening Programmes in the most remote regions of the country. As the global disease burden increases, owing to aging populations, early detection of disease and an increase in chronic/lifestyle diseases, the need for radiology services will increase, which increases the need for AI-assistance and automation in the delivery of these services. The global healthcare AI market is expected to cross $170 billion by 2029, of which almost $20 billion will be in the domain of radiology. Today, of the about 700 AI-based applications which are approved by the US-FDA, 80% are related to radiology. This number is expected to grow exponentially as access to training data and computation power becomes cheaper and easier to access. Alok Goyal, Partner at Stellaris Venture Partners commented: “The volume of imaging scans show a steady 9% year-on-year growth, outpacing the growth in the number of radiologists at a mere 1.8%. Bridging this demand gap is a crucial challenge for healthcare providers, and we believe AI will be the key. CARPL's integrated platform, designed for testing, deploying, and monitoring radiology AI applications, is poised to empower healthcare providers by seamlessly integrating AI into their clinical workflows. We are thrilled to join forces with Vidur and his team on this transformative journey.” As it becomes easier to build AI, the number and nature of AI applications used by doctors to deliver healthcare will increase exponentially. A platform approach that builds on connecting these AI developers to healthcare providers is the only way to exponentially improve the access, affordability and quality of care delivered today. CARPL is a new layer in the healthcare CIO’s stack that enables seamless access to the entire AI and analytics ecosystem through a single integrated platform. About CARPL CARPL is democratizing access to high quality healthcare by connecting AI applications and healthcare providers, exponentially improving the access, affordability and quality of medical care. CARPL enterprise imaging AI platform provides a single user-interface, data channel and procurement system for healthcare providers to access, assess, integrate and buy radiology AI applications in a safe and seamless manner. CARPL was incubated at Mahajan Imaging & Labs, India’s largest radiology service provider, as its technology division focused on building scalable clinical tools for AI validation, deployment and monitoring, under the guidance of Dr Harsh Mahajan, a pioneer in the field of radiology. For more information please visit https://carpl.ai About Stellaris Venture Partners Stellaris is an early-stage tech-focused VC firm that partners with fearless founders who dream big, think differently, and have an unstoppable desire to challenge the status quo. The fund works with these teams at nascent stages to help transform their ideas into resilient businesses. Stellaris does so with a team of seasoned, diverse operators and entrepreneurs who bring significant experience in building businesses and by providing access to some of the most successful founders and professionals. Since its inception in 2017, Stellaris has backed many market leaders such as Mamaearth, Whatfix, Propelld, Turno, Rigi, and others. For more information on Stellaris Venture Partners, visit https://www.stellarisvp.com Contact Details CARPL Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://carpl.ai/

February 01, 2024 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

The Best AI Girl Generator Apps You Must Try 2024

Summit Ventures BV

In today's technologically driven world, AI girl generator apps have gained immense popularity for their ability to create virtual AI companions. With a plethora of options available, we've curated a list of top-notch AI girl generator tools that you should explore in 2024. These applications offer innovative AI girl generation capabilities, providing unique and engaging experiences. Table of Featured AI Girl Generators 1. Introduction to AI Generated Girls 2. Featured AI Girl Generator Tools 2.1 GPTGirlfriend.online 2.2 GlamGirls.ai 2.3 ChaiApp.pro 2.4 AI-Girlfriend.co 2.5 AI-Companion.co 3. Frequently Asked Questions 4. Conclusion Top Five AI Girl Generator Apps The world of AI girl generators has seen significant growth, offering a variety of engaging options. While each application brings its unique features to the table, GPTGirlfriend.online stands out with its exceptionally engaging interactions and a wide range of capabilities. Girlfriend GPT: Your Gateway to AI Generated Girls Girlfriend GPT is an innovative AI-powered tool that brings your favorite AI girl characters to life, offering interactive experiences. This platform provides a wide array of activities, enabling you to create a virtual space for engaging conversations with your AI girl companion. Moreover, GPTGirlfriend.online offers unrestricted content for a diverse experience. Key Features: Empowers you to create your personalized AI girl companion. Allows unrestricted interactions and conversations. Offers affordable premium and deluxe subscription plans. Resumes conversations with long-term memory. Glam Girls AI: Generate your AI Girl in Seconds Glam Girls is renowned for having the best AI generated girls in the space. This platform is designed for those interested in crafting glamorous AI characters. Whether you're looking for AI girls with a sense of style or unique personalities, GlamGirls.ai has you covered. Key Features: Multiple scenarios for AI girl generation. Customizable interface to align with your preferences. Accommodates various interests and preferences in AI girl characters. Chai App: Create AI Girls for NSFW AI Images Chai App offers an intuitive platform for generating AI girls and companions, particularly suited for NSFW AI image generation. This application excels in providing realistic AI chatbot interactions and customization options for your AI girl companions. Key Features: Intuitive navigation for an immersive experience. Realistic chatbot interactions. Allows customization of AI girl companions. Features advanced capabilities for generating AI girls. AI Girlfriend: Personalized AI Girlfriends for Engaging Conversations AI-Girlfriend.co is the perfect choice for those seeking personalized AI girlfriends. This platform allows you to tailor your AI girlfriend according to your preferences. AI-Girlfriend.co creates engaging and realistic interactions with your ideal AI girlfriend character. Key Features: Provides realistic AI companion interactions with varied emotions and backgrounds. Abundance of features available for diverse AI girlfriend interactions. Offers budget-friendly pricing for personalized AI girlfriends. AI Companion: Engage with AI waifus and husbands AI-Companion.co is known for its wide range of character options in the AI girl generator domain. This versatile platform accommodates various conversations and interactions with AI chatbots, offering personalized experiences. Key Features: Support for multiple languages, enhancing accessibility. Personalization options to tailor the chatbot according to individual preferences. Broad spectrum of interests and character types for diverse user needs. Frequently Asked Questions Q: What is an AI girl generator? A: An AI girl generator is a software application that uses artificial intelligence to create virtual AI girl characters for various purposes, such as entertainment, interaction, or chatbot companionship. Q: How do AI girl generators work? A: AI girl generators work by utilizing advanced algorithms and machine learning techniques to generate AI girl characters with customizable traits, personalities, and conversation capabilities. Q: Can a AI girl generator be used for NSFW content? A: Some AI generated girls are designed to cater to NSFW (Not Safe For Work) content, offering options for more mature and adult-themed interactions. However, not all AI girl generator apps support explicit content. Q: Can I customize AI girl characters generated by these tools? A: Yes, most AI girl generator apps allow users to customize AI girl characters by selecting specific traits, appearances, and personalities to create personalized virtual companions. Q: Are there age restrictions for using AI girl generators? A: Yes, to use AI girl generators, users typically need to be at least 18 years old, as these tools may generate content that is intended for adults. Conclusion In the realm of technology, AI generated girls offer a gateway to interactive virtual companionship. These tools have transformed how we connect with AI characters, providing endless entertainment and personal interactions. Whether you seek customizable AI girls, engaging AI girlfriends, or glamorous AI characters, these apps cater to diverse preferences. They bridge the virtual and real worlds, offering a glimpse into the potential of AI companions. This guide has highlighted top AI girl generator apps in 2024, each with unique features. Some may include NSFW content, so choose accordingly. AI girlfriend apps pioneer technological innovation, enabling users to create, personalize, and interact with AI characters. Explore these apps for a distinctive experience in the world of AI companionship. Unlock the potential of AI girl generators today. GPTGirlfriend.online is the most advanced AI companion subscription service with a community of more than 1,000,000 Monthly Active Users. With more than 25,000 characters, it has transformed how people interact with and experience AI. Please refer to our detailed Terms of Use and Community Guidelines for comprehensive information on usage, safety, and ethical considerations on GPTGirlfriend.online Contact Details GPTGirlfriend Business hello@enias.io Company Website https://www.gptgirlfriend.online

February 01, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P

Benzinga

By Jeremy Golden, Benzinga A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear. As part of its randomized phase 2 AMPLIFY-7P study of ELI-002 7P as an adjuvant monotherapy in Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma (PDAC), Elicio Therapeutics Inc. (NYSE: ELTX) has dosed the first patient at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research in New York. ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by seven common mutations in KRAS: G12D, G12R, G12V, G12A, G12C, G12S and G13D. Those are present in 25% of all solid tumor cancers and 88% of PDAC patients. This is in contrast to other KRAS-targeted therapeutics in development, particularly small molecule KRAS inhibitors. Those target fewer mutations – potentially limiting the number of patients who can be treated – while also limiting the duration of benefit due to the development of escape mutants. The AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine. That data demonstrated tumor biomarker reduction, with strong T cell responses that correlated with reduced risk of relapse and death. Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development and Chief Medical Officer, anticipates results from this study will yield definitive data to support clinical efficacy assessment. Initial interim data on ELI-002 7P monotherapy from phase 1A arm will be shared in the first half of 2024, the company said. “Approximately 90% of pancreatic cancers are positive for KRAS mutations, with only rare G12C mutations, about 1%, amenable to small molecule treatment,” Haqq said. “ELI-002 represents a cancer vaccine approach that could potentially address the much broader spectrum of pancreatic cancer KRAS mutations.” In January, Elicio presented a Trial in Progress poster on the design of the AMPLIFY-7P trial at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The poster describes the phase 1 and randomized phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC). “ELI-002 is an off-the-shelf cancer vaccine candidate developed with our proprietary Amphiphile (“AMP”) platform which provides a new ability to deliver these treatments effectively to the ‘command center’ of the immune response – the lymph nodes – where tumor-fighting T cells are generated and equipped,” Haqq said. “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.” “Patients with RAS mutated pancreatic cancers who have positive circulating tumor DNA post-surgery are often quick to relapse,” added Zev A. Wainberg, M.D., Professor of Medicine, University of California, Los Angeles (UCLA), Co-Director, the UCLA GI Oncology Program. “Our current standard of care for these patients is observation — there are no treatments given during this ‘wait and see’ observation window before relapse. As we progress to Phase 2 of the study, we seek to compare ELI-002 7P to our current standard of care to further evaluate its antitumor activity and clinical benefit in the adjuvant setting as well as with bulkier cancer treated at the time of relapse in crossover patients with mKRAS-driven pancreatic cancer.” Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 01, 2024 08:15 AM Eastern Standard Time

Article thumbnail News Release

University of Dayton Law School Leads the Way in Contract Excellence with the Adoption of the NCMA Contract Management Standard™

National Contract Management Association

The University of Dayton School of Law (UDSL) proudly announces its commitment to advancing education in Government Contracting & Procurement through the adoption of the National Contract Management Association's (NCMA) ANSI-approved Contract Management Standard™ (CMS™) and Contract Management Book of Knowledge ® (CMBOK ® ). The Master in the Study of Law (M.S.L.) in Government Contracting & Procurement program at UDSL is dedicated to providing students with the highest quality education and ensuring they are equipped with the knowledge and skills necessary for success in the ever-evolving profession of contract management. By incorporating the NCMA CMS™ and CMBOK ® into its program and course curricula, UDSL reaffirms its commitment to academic excellence and aligns with contract management best practices. Kraig Conrad, CEO of the National Contract Management Association, expressed enthusiasm about the partnership, stating, "We commend the University of Dayton School of Law for taking this progressive step for their program. This standard is a recognized benchmark in the profession, and its incorporation into UDSL's program reflects the university's dedication to providing students with a competitive edge in their careers." The NCMA CMS™ and CMBOK ® will serve as the foundation for UDSL's M.S.L. program, guiding the development of curriculum that addresses the dynamic and complex landscape of government contracting and procurement. This strategic adoption ensures that students receive comprehensive and up-to-date education and prepares them for success in the workforce. In response to the adoption, Sabra Tomb, UDSL’s Director of Training Programs and Strategic Business Development stated, "UDSL’s Government Contracting & Procurement Program is committed to delivering excellence in education and preparing our students to excel in their professional pursuits. The integration of the NCMA Contract Management Standard™ into our program is a testament to our dedication to providing a top-notch education that meets the needs of the industry and empowers our students for success." As UDSL continues to strengthen its position as a leader in legal education, this decision underscores its commitment to staying at the forefront of profession advancements and provide students with a competitive advantage in the job market. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. The School of Law offers a fully online master's program in government contracting and procurement designed by seasoned industry and government experts. The program is designed for contract professionals; a law degree is not required. Courses are taught in real-time to encourage active learning and provide opportunities for live feedback and interaction between faculty and students. Each class meets once a week, scheduled for working professionals. Financial aid, military, and veteran benefits; and corporate and government tuition deferment, assistance and reimbursement options are available. For more visit: https://udayton.edu/law/. Contact Details National Contract Management Association Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 01, 2024 05:00 AM Eastern Standard Time

Article thumbnail News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in New Mexico

NuggMD

NuggMD, the nation's largest medical marijuana telemedicine platform, has launched its industry-leading service in New Mexico, the 28th state the company serves. Since its founding in 2015, NuggMD has connected over one million patients to medical marijuana physicians throughout the United States. New Mexico legalized cannabis for medical purposes in 2007 and for recreational use in 2021. In 2023, medical cannabis sales comprised nearly 26 percent of overall cannabis sales in the state, which totaled more than $50m. New Mexico taxes recreational cannabis at 12 percent, but that excise tax does not apply to the state’s medical sales. Since the inception of legal cannabis programs, sales in New Mexico have totaled more than $915m, according to state data, pulling hundreds of millions of dollars out of the state’s black market for the substance and funneling it into legal businesses that create jobs and contribute to the regional economy. “Where consumers get their cannabis matters a lot,” said Alex Milligan, NuggMD co-founder and CMO. “In California, for instance, our investigation confirmed that the state’s black-market cannabis is laced with pesticides and other contaminants, and the potencies don't match the labels. Purchasing from regulated retailers is the only way for consumers to be sure they’re using safe cannabis that’s honestly advertised.” It costs $99 to get a medical cannabis evaluation in New Mexico using NuggMD. The platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit https://www.nuggmd.com/new-mexico. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

January 31, 2024 05:20 PM Eastern Standard Time

Article thumbnail News Release

February is Pet Dental Health Month

YourUpdateTV

February is Pet Dental Health Month, which serves as a helpful reminder that there’s no better time to start prioritizing your cat or dog’s dental health. Recently, Dr. Danielle Bernal, the global veterinarian for Wellness® WHIMZEES®, participated in a nationwide satellite media tour to discuss Pet Dental Health Month and simple tips to help pet parents establish a dental routine. A video accompanying this announcement is available at: https://youtu.be/KhJpe-HTeGw 70% of cats will experience dental disease in their lifetime, and a vast 80% of dogs – especially small breeds and seniors – are at risk of dental disease. Lack of dental care can lead to inflammation, tartar, gingivitis, periodontal disease, and quality of life issues for your pet. Supporting dental health is vital to the overall wellbeing of both dogs and cats, and a steady dental health routine can significantly reduce the frequency and severity of issues in between visits to the vet. Incorporating a daily dental treat or chew option like Wellness® WHIMZEES® can go a long way toward ensuring pets will have healthier teeth, gums, and breath, and in turn, live happier lives. Wellness® WHIMZEES® allow pet parents to care for their pet’s dental health in an easy, enjoyable way and are crafted to support the 4 areas vets check most: Breath, Plaque, Tartar and Gums. Wellness® WHIMZEES® Brushzees® Natural Dental Treats for dogs are an ideal solution for daily dental care and have been awarded the Veterinary Oral Health Council (VOHC) approval seal. They arescientifically proven to lower plaque and tartar, supporting healthier teeth, gums, and fresher breath. Available in three delicious flavors, Chicken, Chicken & Salmon, and Chicken & Tuna, new Wellness® WHIMZEES® Natural Dental Treats for cats are designed with fresh chicken as the primary ingredient to offer a taste cats love. Wellness Pet’s latest innovation is set to support feline dental care and empower pet parents to treat them well while effortlessly contributing to their furry companions' oral wellbeing and ensuring a delightful experience. Options for both cats and dogs are conveniently available at pet specialty retailers, national retailers and online. To learn more about Wellness® WHIMZEES® and find them near you, visit https:// www.whimzees.com/. About Dr. Danielle Bernal Danielle Bernal, D.V.M., has over a decade of experience in veterinary medicine, specializing in animal nutrition. In her role as on-staff veterinarian at Wellness Pet Company, maker of premium natural food and treats for dogs and cats, including Wellness® WHIMZEES®, she educates pet parents and retailers alike on the importance of natural ingredients like wholesome meats and nutrient-rich superfoods and the highest quality standards. She passionately believes that proper nutrition helps pets lead happier, healthier lives and she shares that message with pet parents. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

January 31, 2024 10:48 AM Eastern Standard Time

Video
Article thumbnail News Release

Cortland Biomedical Expands Cutting-Edge Capabilities and Capacity for Design and Development of Woven Biomedical Textile Structures

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, proudly announces the expansion of its weaving capabilities with the incorporation of two additional Jacquard Looms. This strategic move not only enhances the company's capacities, but also opens new avenues for groundbreaking advancements in medical textiles. Cortland Biomedical, in collaboration with global leaders in weaving equipment, integrates cutting-edge technologies into its machinery, ensuring excellence in every aspect from contact surfaces to yarn tensioning systems. Specializing in plain and narrow weave fabrics, including shuttle and rapier weaving, Cortland Biomedical excels in creating unique three-dimensional structures for applications like vascular grafts. These woven textiles, specifically designed for vascular and abdominal aortic aneurysm grafts and ensure limited blood flow. In addition, these woven textiles prove invaluable in orthopedics for bone and soft tissue repair, combining high strength with flexibility. Cortland Biomedical’s expertise positions it as a premier provider of tailored woven textile solutions for diverse medical applications. The addition of the two Jacquard Looms signifies a leap forward in Cortland Biomedical’s capabilities. This cutting-edge technology allows for unlimited possibilities in fabric design. Manipulating individual warp ends enables the creation of intricate structures, including bifurcations, convergences, tapers, and multi-layered fabrics. The fully electronic Jacquard loom offers unparalleled flexibility in altering fabric structures and patterns, significantly reducing material and time during prototyping. “Agility, curiosity, and credibility are at the heart of our mission, and set us apart as the easy-to-work-with partner our customers can count on to meet their unique medical device needs,” said Eric Brown, general manager, Cortland Biomedical. “Aligned with this strategy, our decision to add these Jacquard Looms was driven by our commitment to expanding capabilities, meeting the growing demands of the medical device industry, and fostering maximum innovation for our customers.” These looms boast the ability to weave thoracic size tubular grafts up to 46mm in diameter, create bifurcated structures as well as tapered flat and tubular structures, and generate infinite pattern designs through computer programming. With electronic let-offs designed for managing fine denier yarns, these looms can weave structures with high density and low permeability using polyesters, aramids, resorbables, and other fibers prominent in the medical device space. Cortland Biomedical will be exhibiting in booth 815 next week at MD&M West in Anaheim, CA. Eric and other company representatives will be on hand to discuss not only the company’s enhanced weaving abilities, but also its collaborative design and engineering processes, and capabilities for knitting, braiding and post-processing. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details SVM Public Relations Jordan Bouclin +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 31, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

PathAI launches six additional oncology indications for PathExplore, an AI-powered pathology panel for spatial analysis of the tumor microenvironment

PathAI

PathAI, a global leader in AI-powered pathology, today announced the launch of six additional oncology indications for PathExplore™, the world’s first structured, standardized and scalable panel for characterization of the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). The additional indications are ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancers. PathExplore first launched in April 2023 with 8 indications, including non-small cell lung, breast, colorectal, skin, gastric, prostate, kidney, and pancreatic cancers. With this expansion, PathExplore human interpretable features (HIFs) will now be available across 14 oncology indications to accelerate the next phase of precision oncology. The last decade has seen significant strides in oncology drug development, but challenges remain – many cancer patients do not respond to available treatments, and many aren’t eligible for potentially transformative therapies because of a lack of actionable biomarkers. Distinct cell populations, tissue structures, and their spatial distributions across the TME represent some of the most promising areas of oncology research, however; traditional approaches are unable to access the full resolution of histopathology data at scale. “Pathology is the only data modality to define and quantify morphological changes resulting from treatment or disease progression,” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. “PathExplore enables researchers and drug developers to effortlessly investigate standard characteristics of the TME, such as the abundance of tumor-infiltrating lymphocytes, as well as spatial characteristics that were previously impossible to measure such as the ratio of lymphocytes to fibroblasts near the epithelial-stromal interface.” Since launch, PathExplore has established itself as the gold-standard in AI-powered digital pathology for oncology drug development. PathAI has partnered with over 50 pharma, biotech, academic, and laboratory partners to analyze >150,000 WSIs, resulting in 50+ publications and presentations. “PathExplore represents a tremendous leap forward in biological research, bypassing long standing constraints of many existing modalities by combining the widespread availability of H&E with the unprecedented resolution of AI,” said Mike Montalto, PhD, chief scientific officer at PathAI. “By expanding the availability of PathExplore’s structured pathology data into new disease areas, we’re empowering drug developers to continue to uncover insights that go beyond existing biomarkers.” To learn more about PathExplore, download our ebook that highlights real-world applications of AI-powered pathology solutions including PathExplore, in various stages of drug development programs. PathExplore is For Research Use Only. Not for use in diagnostic procedures. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Their AI-powered models are rigorously trained and validated with data from more than 15 million annotations and are used to optimize the analysis of pathology samples to improve efficiency and accuracy, while also accelerating drug development. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified laboratory in Memphis, TN. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

January 30, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

American Medical Association Grants Cardio Diagnostics (NASDAQ: CDIO) Reimbursement Codes For AI-Powered Coronary Heart Disease Tests

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics’ AI-driven coronary heart disease (CHD) tests have taken another promising step in their evolution. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, has been assigned two dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA); 0440U for the company’s AI-driven CHD detection test, PrecisionCHD, and 0439U for the company’s AI-driven CHD event (heart attack) risk assessment test, Epi+Gen CHD. Assigned by the American Medical Association (AMA), these two new CPT PLA codes – effective April 1, 2024 – mark a significant step toward payer billing and payment for the company’s groundbreaking tests. The designation will facilitate the broader adoption of PrecisionCHD, an integrated genetic-epigenetic clinical blood test to aid in the diagnosis of CHD, and Epi+Gen CHD for evaluating the likelihood of a patient experiencing a CHD event – mainly a heart attack – within the next three years. Treating A Growing Problem Every year, about 805,000 people in the United States have a heart attack, meaning someone experiences a heart attack every 40 seconds. Heart disease is the leading cause of death for both men and women. According to the CDC, in 2021, heart disease was responsible for the deaths of more than 695,000 Americans – representing one in every five deaths. The most common type of heart disease and the major cause of heart attacks, CHD was responsible for over 375,000 deaths in 2021, and CHD-associated medical costs are estimated to be about $239.9 billion according to an estimate by the CDC in its heart disease fact sheet. Combating this growing problem, Cardio Diagnostics reports that PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. The PrecisionCHD test has the ability to aid in the diagnosis of CHD and provide personalized insights to help prevent a heart attack and improve outcomes. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence, along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Identifying patients with CHD and intervening before a heart attack occurs are essential to reducing the unprecedented economic and health burden associated with CHD. Until now, the lack of readily accessible and cost-effective diagnostic solutions for CHD has posed a challenge leading to delayed diagnosis and care, particularly among underserved and minority populations. Increasing access, the PrecisionCHD test only requires a simple blood draw and can be deployed remotely, allowing it to be scaled without the need for specialized infrastructure. This enables more timely intervention and management. “Receiving a dedicated CPT PLA code for PrecisionCHD is a critical milestone in our commercialization strategy,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “With PrecisionCHD, we believe that expanding equitable access to CHD diagnostics and improving patient health outcomes while reducing healthcare expenditure is possible.” While PrecisionCHD aids in diagnosing CHD, Cardio Diagnostics’ Epi+Gen CHD evaluates an individual’s genetic and epigenetics to predict their risk for a heart attack or sudden cardiac death associated with CHD. By leveraging the powerful personalized insights driven by the company’s groundbreaking epigenetic-genetic technology, the company can provide patient-specific epigenetic and genetic drivers of CHD to help guide preventive care that could potentially save lives. In peer-reviewed studies, Epi+Gen CHD was more cost-effective and sensitive for assessing heart attack risk when compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. For employers, the financial burden of heart attacks includes direct costs related to diagnosing, managing and treating heart disease. Indirect costs include lost productivity due to employee absenteeism and short-term disability, which can indirectly cost employers about $1,119 per month for upwards of three years. Cardio Diagnostics’ technology can help employers better inform their benefits offerings by combining the ability to offer employees the advanced Epi+Gen CHD heart attack risk test with aggregated risk data. Cardio Diagnostics’ Employer Risk Intelligence platform provides employers and brokers with the first-of-its-kind cardiovascular employee population health intelligence backed by a clinical test and layered insights, completed in a compliant manner. As such, Epi+Gen CHD’s new reimbursement code could mean greater access to technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. “Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers,” Dogan said. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks. The company is committed to making heart disease risk assessment, detection and management more accessible, and it believes personalized and precise diagnostics are key to winning the fight against the leading cause of death in the United States. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

January 30, 2024 08:20 AM Eastern Standard Time

1 ... 4849505152 ... 250